Minia University Hospitals - Department of Surgery, Faculty of Medicine, Minia University
Minya, Minya Governorate, 61519, Egypt
NCT Number: NCT07725718
Abdominal wall reconstruction (AWR) with mesh is the standard repair for ventral, incisional, parastomal and complex abdominal wall defects, but mesh-related infection remains one of its most serious complications - prolonging hospital stay, often requiring reoperation or removal of the mesh, and increasing the risk of hernia recurrence. Reported infection rates vary widely, and the independent contribution of individual risk factors remains uncertain, in large part because much of the existing evidence comes from retrospective series with inconsistent outcome definitions.
This single-centre, prospective observational cohort study will enrol consecutive adults undergoing elective or urgent AWR with synthetic, biosynthetic or biological mesh at a tertiary referral hernia unit. Participants will be followed for 12 months on a fixed schedule (7-10 days, 30 days, 90 days, 6 months and 12 months). Using internationally accepted, prespecified definitions of mesh infection and surgical site occurrence, the study will collect up to 18 candidate patient, defect, operative and perioperative risk factors and analyse them by multivariable logistic regression to identify the independent predictors of mesh-related infection within 90 days of surgery.
Secondary aims are to describe the incidence, timing, microbiology and management (salvage versus explantation) of mesh infection; to report surgical site occurrences and reoperation; and to derive an exploratory risk-stratification model. The findings are intended to support preoperative risk assessment, targeted patient optimisation, informed mesh and technique selection, and shared decision-making. The study is designed and reported in accordance with the STROBE statement.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Minya, Minya Governorate, 61519, Egypt
Design and setting. A prospective, single-centre observational cohort study conducted at a tertiary referral hernia and abdominal wall surgery unit (Department of Surgery, Faculty of Medicine, Minia University, Egypt). Consecutive eligible adults undergoing AWR with mesh are enrolled at the time of surgery and followed prospectively. No study-specific intervention is imposed; surgical and perioperative management follow routine unit practice, and exposures (candidate risk factors) are observed rather than assigned.
Study period. The study runs for 24 months in total, from 15 August 2026 to 15 August 2028. Consecutive enrolment takes place over the first 12 months (15 August 2026 - 15 August 2027); each participant is then followed for 12 months, so that the last enrolled participant completes follow-up at the end of month 24. The 90-day primary-outcome window closes for the final participant in November 2027.
Objectives. The primary objective is to identify the independent risk factors associated with mesh-related infection within 90 days of AWR. Secondary objectives are to estimate the cumulative incidence and timing of mesh infection; to characterise its microbiology and the proportion managed by mesh salvage versus partial or complete explantation; to describe surgical site occurrence (SSO) and SSO requiring procedural intervention (SSOPI); to derive an exploratory, prespecified risk-stratification model and assess its discrimination and calibration; and to evaluate the association of mesh infection with hernia recurrence and reoperation at 12 months.
Primary outcome. Mesh-related infection within 90 days, confirmed by at least one of: purulent drainage from a peri-mesh space in contact with the prosthesis; positive microbiological culture from peri-mesh fluid, explanted mesh or an image-guided/operative peri-mesh specimen; cross-sectional imaging (preferably contrast-enhanced CT) demonstrating a peri-mesh collection or abscess with clinical signs of infection; or the need for operative or percutaneous intervention directed at infected mesh. Superficial incisional infection without mesh involvement is recorded separately, and deep or organ/space infection is coded using CDC/NHSN criteria.
Candidate predictors. Up to 18 prespecified variables across four domains - patient (age, sex, BMI/obesity, active smoking, diabetes and HbA1c, serum albumin, ASA class, immunosuppression, COPD), defect (defect width by EHS grouping, recurrent hernia, loss of domain, CDC wound class, VHWG grade, stoma/parastomal defect), operative (mesh type and position, component separation including transversus abdominis release, operative time, concomitant bowel procedure, estimated blood loss, drain use) and perioperative (antibiotic-prophylaxis appropriateness, intraoperative normothermia and glycaemia, transfusion, early SSO).
Follow-up. Participants are reviewed at baseline/operation and at 7-10 days, 30 days, 90 days (primary outcome), 6 months and 12 months. Outcome events are adjudicated against the prespecified definitions by two investigators, with disagreements resolved by consensus.
Sample size and analysis. Target enrolment is 420 participants (≈380 evaluable after ≈10% attrition; ≈53 expected events), sized to support a stable multivariable logistic regression model (events-per-variable ≥10) and precise estimation of infection incidence. Candidate predictors are analysed by univariable tests and multivariable logistic regression with adjusted odds ratios and 95% confidence intervals; Firth penalised likelihood or LASSO is used where events are limited. Model discrimination (c-statistic) and calibration (Hosmer-Lemeshow test, calibration plot) are assessed with optimism-corrected internal validation by bootstrapping. Prespecified secondary and sensitivity analyses include time-to-event modelling and subgroup analyses by mesh type, mesh position and wound contamination class.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Within 90 days after surgery
Proportion of participants with mesh-related infection, defined as infection involving the implanted mesh confirmed by at least one of: purulent drainage from the wound or a peri-mesh space in contact with the prosthesis; positive microbiological culture from peri-mesh fluid, the explanted mesh, or an image-guided/operative peri-mesh specimen; cross-sectional imaging (preferably contrast-enhanced CT) demonstrating a peri-mesh collection or abscess with clinical signs of infection; or the need for operative or percutaneous intervention directed at infected mesh, including partial or complete explantation for infection.
Time frame: Through 12 months after surgery
Cumulative incidence of mesh-related infection over the full follow-up period, and the timing (days from surgery) of each confirmed event, summarised by time-to-event methods.
Time frame: Through 12 months after surgery
Distribution of causative micro-organisms isolated from peri-mesh specimens among participants with confirmed mesh infection
Time frame: Through 12 months after surgery
Proportion of confirmed mesh infections managed by successful mesh salvage (non-operative/conservative measures) versus partial or complete mesh explantation.
Time frame: 30 days, 90 days and 12 months after surgery
Proportion of participants with any surgical site occurrence (seroma, haematoma, surgical site infection, wound dehiscence, skin/soft-tissue necrosis, or enterocutaneous fistula) per the Ventral Hernia Outcomes Collaboration definitions.
Time frame: 30 days, 90 days and 12 months after surgery
Proportion of participants with any SSO requiring procedural intervention (bedside opening, percutaneous drainage, or reoperation).
Time frame: 30 days after surgery
Proportion of participants with superficial incisional, deep incisional, and organ/space surgical site infection
Time frame: 12 months after surgery
Proportion of participants with clinically or radiologically confirmed hernia recurrence at the repair site.
Time frame: 12 months after surgery
Proportion of participants undergoing any unplanned return to theatre related to the index abdominal wall reconstruction.
Time frame: At completion of follow-up and analysis (up to 42 months)
Discrimination (area under the ROC curve / c-statistic) and calibration (Hosmer-Lemeshow test and calibration plot, with optimism-corrected internal validation by bootstrapping) of the prespecified multivariable risk-stratification model for mesh-related infection.
Contact information is provided by the study sponsor or research team.
Minia University
Other
Risk Factors for Mesh-Related Infection in Abdominal Wall Reconstruction: A Single-Centre Prospective Observational Cohort Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07720154
Abdominal Hernia, Complex Ventral Hernia
Minya, Minya Governorate, Egypt
View Trial DetailsNCT06364306
Abdominal Wall Defect, Hernia
Kempten (Allgäu), Bavaria, Germany
View Trial DetailsNCT07360691
Abdominal Wall Hernia, Hernia
Mandya, Karnataka, India
View Trial DetailsNCT06864377
Hernia, Hernia, Abdominal
Køge, Denmark
View Trial Details